Nkarta Inc. (NKTX) News
Filter NKTX News Items
NKTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NKTX News From Around the Web
Below are the latest news stories about Nkarta Inc that investors may wish to consider to help them evaluate NKTX as an investment opportunity.
William Blair Initiates a Buy Rating on Nkarta (NKTX)William Blair analyst Sami Corwin initiated coverage with a Buy rating on Nkarta (NKTX – Research Report) today. The company's shares closed last Wednesday at $13.76, close to its 52-week low of $12.46. Currently, the analyst consensus on Nkarta is a Strong Buy with an average price target of $67.00. See Insiders’ Hot Stocks on TipRanks >> Based on Nkarta's latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $22.35 million. In comparison, last year the company had a GAAP net loss of $13.69 million. |
Do Institutions Own Nkarta, Inc. (NASDAQ:NKTX) Shares?Every investor in Nkarta, Inc. ( NASDAQ:NKTX ) should be aware of the most powerful shareholder groups. Institutions... |
Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AMLSOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NKX101 for treatment of acute myeloid leukemia (AML). |
Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and ExpositionSOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today presented a trial in progress poster on NKX019 for the treatment of relapsed and refractory B-cell malignancies at the 63 rd Annual Meeting and Exposition of the American Society of Hematology (ASH). |
Charles Schwab Investment Management Inc. Has $3.41 Million Holdings in Nkarta, Inc. (NASDAQ:NKTX)Charles Schwab Investment Management Inc. reduced its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 9.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,615 shares of the companys stock after selling 11,482 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately [] |
15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA CapitalIn this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five stocks in this list, head on over to 5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA […] |
Nkarta, Inc. (NASDAQ:NKTX) Shares Sold by Northern Trust CorpNorthern Trust Corp cut its stake in shares of Nkarta, Inc. (NASDAQ:NKTX) by 28.0% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 159,529 shares of the companys stock after selling 62,111 shares during the period. Northern Trust Corp owned approximately 0.49% of Nkarta worth $5,056,000 at [] |
At Current Prices, Nkarta Inc. (NASDAQ: NKTX) Worth A Patient Look?Nkarta Inc. (NASDAQ:NKTX)s traded shares stood at 0.44 million during the last session. At the close of trading, the stocks price was $17.37, to imply a decrease of -2.47% or -$0.44 in intraday trading. The NKTX shares 52-week high remains $79.16, putting it -355.73% down since that peak but still an impressive 10.13% since price At Current Prices, Nkarta Inc. (NASDAQ: NKTX) Worth A Patient Look? Read More » |
Nkarta (NASDAQ:NKTX) Now Covered by Sumitomo Mitsui Financial GroupResearch analysts at Sumitomo Mitsui Financial Group began coverage on shares of Nkarta (NASDAQ:NKTX) in a research note issued on Thursday, Briefing.com reports. The firm set an outperform rating and a $50.00 price target on the stock. Sumitomo Mitsui Financial Groups price target indicates a potential upside of 185.55% from the stocks previous close. Several [] |
Can Nkarta (NKTX) Climb 270% to Reach the Level Wall Street Analysts Expect?The mean of analysts' price targets for Nkarta (NKTX) points to a 270.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |